Nancy U. Lin, MD

Dr. Lin is a medical oncologist at Dana-Farber Cancer Institute focusing on the care of women with breast cancer. Her research focuses upon developing novel therapies for women with brain metastases, and upon exploring mechanisms of resistance and response to HER2-based therapy.

EDUCATIONAL TITLES

  • Associate Professor, Medicine, Harvard Medical School

  • Active Staff, Adult Oncology, Dana-Farber Cancer Institute

  • Clinical Director, Breast Oncology Center, Medical Oncology, Dana-Farber Cancer Institute

Education: Harvard Medical School (1995–1999)

Books: 100 Questions & Answers About Triple Negative Breast Cancer

Podcast Appearances
Dr. Nancy Lin: Are CNS Mets Becoming More Treatable? What’s New with STOP-HER2?

Brain metastases are unfortunately an all too common and devastating complication of breast cancer. The blood-brain barrier has long been a key obstacle to developing effective systemic therapies; however, newer agents are showing signs of overcoming this challenge. Dr. Nancy Lin explains.

Road to a Cure - Dr. Heather Parsons & Dr. Nancy Lin

The Road to a Cure series heads to Boston to have Senior Producer and Co-host, Victoria Goldberg and co-host Dr. Paula Jayne speak with Dr. Nancy Lin and Dr. Heather Parsons about the possibilities and the current barriers to considering a cure for HER2+ MBC. Dr. Parsons and Dr. Lin are medical oncologists and professors at Harvard Medical School. Dr. Lin is also the Director of the Metastatic Breast Cancer Program and the Associate Chief of the Division of Breast Oncology at Dana Farber Cancer Institute. While an amazing gift, long-term survival among some HER2+ patients can also sometimes bring special challenges. Given the higher prevalence of brain metastases among HER2+ patients, Drs. Lin and Parsons also discuss current research on brain mets, along with areas of promising overall MBC research for each subtype.

Nancy U. Lin, MD

A conversation with Dr. Nancy Lin, Director of the Metastatic Breast Cancer Program at Dana-Farber Cancer Institute.

Next

Stephanie Graff, MD